In April 2026, Canada’s Drug Agency (CDA) unveiled an expanded dataset, offering a comprehensive look at the trends and intricacies of its drug approval and reimbursement system. This significant update builds upon the agency’s initial data release in November 2025, which focused on drug submissions to Health Canada and the CDA’s Drug Reimbursement Review program. The newly released dataset delves deeper, incorporating insights into health technology assessment (HTA) timelines and covering the period from 2020 to 2024, providing a crucial five-year retrospective on the Canadian pharmaceutical regulatory environment.
Declining Drug Approvals Amidst Shifting Submission Strategies
The expanded data reveals a notable trend in the number of drugs receiving Health Canada approval. In 2024, a total of 111 drugs were approved, a modest increase from the 106 approvals in 2023. However, this figure represents a discernible downward trajectory when compared to earlier years within the analyzed period. In 2020, Canada saw 150 drug approvals, followed by 145 in 2021 and 123 in 2022. This decline in overall approvals suggests a potential tightening of regulatory standards or a shift in the types of therapies being submitted for review.
Concurrently, the number of drug submissions to the CDA for HTA reimbursement review has remained relatively stable, averaging around 48.5% of new drug approvals between 2020 and 2024. This stability in submission rates, despite the dip in overall approvals, points to a strategic evolution among pharmaceutical manufacturers. A significant development highlighted by the data is the increasing preference for submitting to the CDA for an HTA review pre-Notice of Compliance (NOC) from Health Canada. Pre-NOC submissions to the CDA saw a consistent rise, growing from 29 in 2020 to 54 in 2024. Conversely, post-NOC submissions experienced a steady decline, dropping from 32 in 2020 to 22 in 2024.
This strategic shift towards earlier engagement with the CDA for HTA reviews, even before final Health Canada approval, is further underscored by the timing of CDA recommendations. The number of pre-NOC recommendations issued by the CDA increased from 35 in 2020 to 52 in 2024. In contrast, post-NOC recommendations saw a decrease, falling from 24 in 2020 to 20 in 2024. The data for 2024 indicates that 66% of completed pre-NOC reviews involved submissions filed with the CDA at least 91 days before regulatory approval. For post-NOC submissions in the same year, 45% were filed with the CDA within 90 days of Health Canada approval, and a significant 30% were submitted over a year after approval, highlighting the extended timelines associated with later-stage submissions.
Positive Reimbursement Trends Mask Evolving Conditions
Over the 2020-2024 period, the CDA has generally issued an increasing number of positive reimbursement recommendations. In 2020, 81% of recommendations were positive, a figure that climbed to 94% in 2024. However, a closer examination reveals a critical evolution in the nature of these positive recommendations. In 2020, the CDA issued three "reimburse-only" recommendations and 45 recommendations with specific clinical criteria and/or conditions. Since then, all positive recommendations have incorporated a clinical criterion and/or condition. This indicates a clear move towards a more stringent approach, where reimbursement is increasingly contingent upon meeting defined clinical benchmarks or fulfilling specific therapeutic needs.
A significant innovation introduced in 2024 is the "time-limited reimbursement recommendation." This new program aims to expedite access to drugs for severe or rare diseases, allowing manufacturers time to gather additional clinical data. Drugs receiving this designation will undergo a reassessment once the required data is submitted within a predetermined timeframe. While the overall trend of positive recommendations is encouraging, the mandatory inclusion of clinical criteria or price reduction conditions in all positive recommendations signifies a sustained focus on demonstrating value and clinical utility.
The implications of these trends are substantial for pharmaceutical companies. The shift towards pre-NOC submissions suggests a proactive approach to market access, allowing companies to align their development and regulatory strategies with HTA requirements early on. This can potentially streamline the overall market access process and reduce the risk of delays post-Health Canada approval. However, the increasing stringency of reimbursement conditions necessitates robust clinical trial designs and evidence generation strategies that can clearly demonstrate a drug’s benefit over existing therapies.
Streamlined HTA Review Timelines, Yet Reimbursement Delays Persist
Despite the increasing complexity of reimbursement conditions, the HTA review timelines themselves have shown marked improvement. In 2020, 78% of HTA reviews received a draft recommendation within 180 days of acceptance for review. This figure steadily rose to 92% in 2024, indicating greater efficiency within the CDA’s review process. Reviews that exceeded the 180-day deadline were typically attributed to suspensions, pending requests for additional information, or recommendations from CDA drug expert committees to delay the review post-NOC.
Furthermore, the CDA observed a decline in the median overall HTA review time from submission to final recommendation. In 2020, the median review time was 235 days, which decreased to 206 days in 2024, marking the shortest median review time within the analyzed five-year period. This suggests that the CDA has successfully optimized its internal processes to deliver recommendations more swiftly.
However, a stark contrast emerges when analyzing the average time to reimbursement for branded drugs, as reported by GlobalData’s Price Intelligence (POLI) database. For branded medicines with a first reimbursement date in 2020, the average time from approval to reimbursement was 440 days. This figure more than doubled to 967 days for branded products with a first reimbursement date in 2024. This widening gap between HTA decision-making and actual reimbursement underscores the significant complexities that arise after a CDA review.
The Post-HTA Gauntlet: Negotiations and Provincial Listings
The extended time to reimbursement highlights the intricate post-HTA landscape in Canada. Even after receiving a positive recommendation from the CDA, manufacturers must navigate a multi-layered process involving negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA). The pCPA negotiates drug prices on behalf of provincial and territorial governments, aiming to secure cost-effective access to new medicines for public drug plans. These negotiations can be lengthy and complex, often involving substantial price reductions or volume-based agreements.
Following successful pCPA negotiations, the process does not conclude. Manufacturers then face the challenge of securing individual provincial and territorial government drug plan listings. Each jurisdiction has its own formulary and listing criteria, necessitating further engagement and adherence to specific provincial requirements. This fragmented system, where national HTA recommendations must be translated into individual provincial access, contributes significantly to the extended timelines observed in the reimbursement process.
The GlobalData POLI data, illustrating this growing delay, paints a picture of a system where efficient HTA reviews are a necessary but not sufficient condition for timely patient access. The complexities of pricing negotiations and provincial adoption are the primary drivers of the protracted journey from drug approval to widespread reimbursement.
Implications for Pharmaceutical Market Strategy and Future Access
The comprehensive data released by the CDA offers unprecedented transparency into the timelines and processes governing drug approvals and reimbursement in Canada. This information is invaluable for pharmaceutical industry stakeholders seeking to navigate the country’s uniquely complex regulatory environment, characterized by extensive HTA reviews and rigorous pricing negotiations.
For pharmaceutical companies, this data can inform critical market access strategies. Understanding the nuances of the HTA process, the evolving criteria for positive recommendations, and the timelines associated with each stage can enable more accurate forecasting and strategic planning. Companies can leverage this information to synchronize global launch plans, optimize the allocation of commercial resources, and scale their supply chains in alignment with projected regulatory and reimbursement timelines.
The trend towards earlier engagement with the CDA through pre-NOC submissions suggests that a proactive approach to market access, integrated into the drug development lifecycle, is becoming increasingly crucial. Furthermore, the emphasis on clinical criteria and the introduction of time-limited reimbursement recommendations highlight the need for robust clinical evidence generation and a clear demonstration of a drug’s value proposition in the Canadian context.
The ongoing challenges in bridging the gap between HTA recommendations and actual reimbursement underscore the persistent need for dialogue and potential reform within the broader market access ecosystem, including the pCPA and provincial drug plans. While the CDA’s efforts have improved internal review efficiencies, the downstream complexities remain a significant hurdle to timely patient access to innovative therapies. As Canada continues to evolve its approach to drug assessment and reimbursement, this detailed data from the CDA will serve as a vital tool for all stakeholders striving to enhance both the efficiency and equity of pharmaceutical access for Canadians.
